DHX9-IN-2

CAS No. 2973395-71-8

DHX9-IN-2( —— )

Catalog No. M37315 CAS No. 2973395-71-8

DHX9-IN-2 is an inhibitor targeting ATP-dependent RNA de-helicase A (DHX9) with anticancer and antitumor activity for cancer research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 265 In Stock
5MG 242 In Stock
10MG 376 In Stock
25MG 539 In Stock
50MG 685 In Stock
100MG 886 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    DHX9-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    DHX9-IN-2 is an inhibitor targeting ATP-dependent RNA de-helicase A (DHX9) with anticancer and antitumor activity for cancer research.
  • Description
    DHX9-IN-2 (example 31)is an inhibitor of ATP-dependent RNA helicase A (DHX9), with the IC50 of 0.0698 nM that has antitumor activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    DNA/RNA Synthesis
  • Recptor
    DNA/RNA Synthesis
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2973395-71-8
  • Formula Weight
    421.92
  • Molecular Formula
    C18H16ClN3O3S2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (237.01 mM; Ultrasonic )
  • SMILES
    O=C(NC1=CC(Cl)=CC(=C1)NS(=O)(=O)C)C=2SC=C(C2)C=3N=CC=CC3C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. DANIELS Matthew H., et al. Preparation of imidazopyridines, thienopyrimidines, pyrrolopyrimidines and related heterocycles as inhibitors of RNA helicase DHX9 useful in treatment of cancers. World Intellectual Property Organization, WO2023154519 A1 2023-08-17
molnova catalog
related products
  • Helicid

    Helicid is a medicine available in a number of countries worldwide.

  • Mithramycin A

    A tricyclic pentaglycosidic, antineoplastic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA.

  • SMN-C3

    SMN-C3 (MV8T2MCK57) is an orally active modulator of SMN2 splicing, and has the potential to treat spinal muscular atrophy (SMA).